| 10 |
2021.01.29 |
Resolutions for Convocation of General Meeting of Shareholders |
Aptabio Therapeutics Inc. |
| 9 |
2021.01.29 |
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) |
Aptabio Therapeutics Inc. |
| 8 |
2020.12.31 |
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청) |
Aptabio Therapeutics Inc. |
| 7 |
2020.12.11 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder)) |
Aptabio Therapeutics Inc. |
| 6 |
2020.12.09 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(안질환 치료용 조성물) |
Aptabio Therapeutics Inc. |
| 5 |
2020.08.20 |
Additional Listing(주식매수선택권행사) |
Aptabio Therapeutics Inc. |
| 4 |
2020.08.03 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 3 |
2020.06.19 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물) |
Aptabio Therapeutics Inc. |
| 2 |
2020.06.12 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
| 1 |
2020.06.10 |
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) |
Aptabio Therapeutics Inc. |
